The FDA has approved AbbVie's Decnupaz, a treatment for rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN) that was one of the assets in its $10.1 billion takeover of ImmunoGen in ...

May 27 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved AbbVie's drug to treat blastic plasmacytoid ...

Abbvie received approval from the Food and Drug Administration for its drug treating people with a rare form of blood cancer. Decnupaz was approved to treat adults with Blastic Plasmacytoid Dendritic ...

DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient ...

AbbVie’s ABBV oncology portfolio delivered a slight decline in the first quarter of 2026, as the segment was affected by weak ...

As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets has crossed the FDA ...

AbbVie Inc. (NYSE:ABBV) ranks among the best retirement stocks to buy now. Piper Sandler increased its price target for AbbVie Inc. (NYSE:ABBV) to $298 from $294 on May 14, retaining an Overweight ...

AbbVie's revenue for the first quarter came in at $15 billion, 12.4% higher than the year-ago period. The company had ...

A year after a major layoff round at its Allergan headquarters in California, AbbVie is making more edits to its workforce with a new round of 85 layoffs.  | The layoffs at AbbVie's Irvine, California ...

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

AbbVie (NYSE:ABBV) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The stock is down 7.03% year-to-date as of mid-April 2026, sitting at $208.99, and ...